Author:
Nakamura Masatoshi,Mizumoto Masashi,Saito Takashi,Shimizu Shosei,Li Yinuo,Oshiro Yoshiko,Inaba Masako,Hosaka Sho,Fukushima Hiroko,Suzuki Ryoko,Iizumi Takashi,Nakai Kei,Maruo Kazushi,Sakurai Hideyuki
Abstract
IntroductionChondrosarcoma is a rare malignant bone tumor. Particle beam therapy (PT) can concentrate doses to targets while reducing adverse events. A meta-analysis based on a literature review was performed to examine the efficacy of PT and photon radiotherapy for skull base chondrosarcoma.MethodsThe meta-analysis was conducted using 21 articles published from 1990 to 2022.ResultsAfter PT, the 3- and 5-year overall survival (OS) rates were 94.1% (95% confidence interval [CI]: 91.0-96.2%) and 93.9% (95% CI: 90.6-96.1%), respectively, and the 3- and 5-year local control rates were 95.4% (95% CI: 92.0-97.4%) and 90.1% (95% CI: 76.8-96.0%), respectively. Meta-regression analysis revealed a significant association of PT with a superior 5-year OS rate compared to three-dimensional conformal radiotherapy (p < 0.001). In the studies used in the meta-analysis, the major adverse event of grade 2 or higher was temporal lobe necrosis (incidence 1-18%, median 7%).ConclusionPT for skull base chondrosarcoma had a good outcome and may be a valuable option among radiotherapy modalities. However, high-dose postoperative irradiation of skull base chondrosarcoma can cause adverse events such as temporal lobe necrosis.